Drug Combinations That May Cause Major Drug Interactions Common Among Seniors Who Take Antidepressants, According To Thomson Reuters Research
ANN ARBOR, Mich., Dec. 17, 2010 /PRNewswire/ -- More than half of older Americans who were prescribed antidepressants for the first time were already taking a medication that could adversely interact with the antidepressant , according to a new study from Thomson Reuters.
For one-fourth of the seniors in the study, these were potentially major drug interactions.
The research, published by the American Journal for Geriatric Psychiatry, illustrates the complexity and challenges of prescribing antidepressants to older patients.
"We found a concerning degree of potentially harmful drug combinations being prescribed to seniors," said Tami Mark, Ph.D., the paper's lead author and director of analytic strategies at Thomson Reuters.Among the 39,512 new antidepressant users in the study, 25.4 percent were prescribed antidepressants and another medication that could cause a major interaction. An additional 36.1 percent had potential moderate interactions and 38.5 percent had minor or no interactions. Pain medications were most often identified as having the potential for major interactions with antidepressants, accounting for more than one quarter of all potential major interactions among seniors in the study. "These findings reinforce the need for clinicians to be aware of potential drug-drug interactions and the importance of close patients monitoring," Mark said. The presence of contraindications or interactions increased the probability of patients switching antidepressants by 19.5 percent. The study also found that 5.6 percent of study subjects had a documented side effect from the antidepressants they were prescribed, most often insomnia, somnolence and drowsiness. Overall, the presence of a side effect was associated with a 4.7 percentage point increase in drug switching (from 16.5% to 21.7%) and a 3.7 percentage point increase in discontinuation of treatment (from 22% to 25.7%). Data for the study were derived from the Thomson Reuters MarketScan® database of Medicare claims. Potential drug interactions were identified using Thomson Reuters DRUG-REAX® System. Study subjects, who were aged 65 years or older, were new antidepressant users who were diagnosed with depression between July 1, 2001, and December 31, 2006. The study was funded by Sanofi Aventis. Co-authors include Vijay N. Joish, Ph.D., now with Bayer Pharmaceuticals; Joel W. Hay, Ph.D, from the University of Southern California School of Pharmacy; and David V. Sheehan, M.D., M.B.A., from the University of South Florida College of Medicine. An abstract is available here: http://journals.lww.com/ajgponline/Abstract/publishahead/Antidepressant_Use_in_Geriatric_Populations__The.99747.aspx About Thomson Reuters Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs 55,000 people and operates in over 100 countries. For more information, go to www.thomsonreuters.com. SOURCE Thomson Reuters Healthcare
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV